inhibitor

(redirected from aromatase inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
See: deterrent
References in periodicals archive ?
However, if you're taking vitamin D to protect against the pain from aromatase inhibitors, D2 might be better.
Aromatase inhibitors have become the treatment of choice in the adjuvant setting and monitoring of AI-induced bone loss is critical, particularly in patients with low BMD or low BMI.
In summary, these results, based on single-point sampling of LH, testosterone, and estradiol concentrations before and after the administration of the aromatase inhibitor anastrazole, indicate alleviation of hypogonadotropic hypogonadism in these patients.
Prior studies have shown that resistance to aromatase inhibitors develops due to increased activity in growth factor signaling pathways, and decreased levels of estrogen receptor-alpha (ERa).
Over the past few years, many studies have been published concerning the relative efficacy and safety profiles of tamoxifen and the aromatase inhibitors as adjuvant therapy for postmenopausal women with early hormone receptor-positive breast cancer.
Indeed, no one knows how long the benefits of tamoxifen or the aromatase inhibitors might linger.
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
In participants also receiving the aromatase inhibitor, increases in body fat were seen at all testosterone dose levels, but suppressing estrogen production had no effect on lean mass, muscle size or leg strength.
CHICAGO - The bone loss associated with aromatase inhibitors was significantly slowed with increasing supplements of vitamin D in a prospective cohort study of 156 postmenopausal women.
Five years of extended aromatase inhibitor therapy led to significantly improved disease-free survival in the National Cancer Institute of Canada Clinical Trials Group MA 17 trial, even with a median 3-year and maximum 6-year delay between completion of the tamoxifen regimen and the start of letrozole, Dr.
In this study, five women allocated to treatment with tamoxifen and 12 women allocated to treatment with an aromatase inhibitor (five with letrozole, four with exemestane and three with anastrozole) were followed prospectively for 6 months after the commencement of adjuvant endocrine treatment.
Femara is the only aromatase inhibitor to have a licence in the extended adjuvant setting.